Oncofactory

Oncofactory, a spin-off of the CNRS, is a science-driven biotech company that provides pharmaceutical and biotech companies with innovative in vivo services to support their non-clinical programs in oncology. Oncofactory joined the ERBC Group in December 2022 to extend its technology to a wider range of customers and provide a one-stop shop for non-clinical studies. 🥚Oncofactory unique technology platform is a New Approach Methodology (NAM) to generate patient tumor replicas in avian embryos (AVI-PDX™), coupled with state-of-the-art 3D imaging and large-scale molecular analysis for rapid assessment of therapeutic efficacy and in-depth characterization of mechanisms of action to evaluate therapeutic candidates. Oncofactory, is revolutionizing the process of evaluating cancer treatments using in vivo models that are unmatched in speed, scientific robustness, predictivity and ethical compliance (3Rs). Based on an AVI-PDX model using human tumor cells transplanted into the avian embryo, Oncofactory provides predictive efficacy results in a remarkable timeframe of ten days. This approach outperforms traditional in vivo models and facilitates rapid assessment of treatment efficacy in humans, whether the treatment is chemical, biological, or a combination of molecules. 🥇 With 10 years of process development, the company holds 2 exclusive patent licenses and 1 patent for the platform, 3 innovations awards (Concours Mondial d'Innovation, CNRS pre-maturation program, I-Lab BPIfrance) and 2 scientific awards (CLARA ResearchToBusiness Oncology Trophy, HCL-Lyonbiopole Clinical innovation call). Oncofactory provides solutions for a wide range of non-clinical studies: from drug discovery to the evaluation of monotherapies and combinations of therapies. Oncofactory's innovative technology platform is trusted by major pharmaceutical and biotech companies. They rely on our models to accelerate the development of their drug candidates while ensuring robustness and accuracy.